The first approval in metastatic breast cancer came in 2019 with the approval of atezolizumab in combination with nab-paclitaxel for patients with PD-L1-positive (tumor-infiltrating immune cells ≥ 1%) metastatic triple-negative breast cancer (TNBC) (5). Here, CD274 is linked to neoplasm.